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Objective: Appropriate glucose levels are essential for survival; thus, the detection and correction of low blood glucose is of paramount importance.
Hypoglycemia prompts an integrated response involving reduction in insulin release and secretion of key counter-regulatory hormones glucagon and
epinephrine that together promote endogenous glucose production to restore normoglycemia. However, specifically how this response is
orchestrated remains to be fully clarified. The low affinity hexokinase glucokinase is found in glucose-sensing cells involved in glucose homeostasis
including pancreatic b-cells and in certain brain areas. Here, we aimed to examine the role of glucokinase in triggering counter-regulatory hormonal
responses to hypoglycemia, hypothesizing that reduced glucokinase activity would lead to increased and/or earlier triggering of responses.
Methods: Hyperinsulinemic glucose clamps were performed to examine counter-regulatory responses to controlled hypoglycemic challenges
created in humans with monogenic diabetes resulting from heterozygous glucokinase mutations (GCK-MODY). To examine the relative impor-
tance of glucokinase in different sensing areas, we then examined responses to clamped hypoglycemia in mice with molecularly defined
disruption of whole body and/or brain glucokinase.
Results: GCK-MODY patients displayed increased and earlier glucagon responses during hypoglycemia compared with a group of glycemia-
matched patients with type 2 diabetes. Consistent with this, glucagon responses to hypoglycemia were also increased in I366F mice with
mutated glucokinase and in streptozotocin-treated b-cell ablated diabetic I366F mice. Glucagon responses were normal in conditional brain
glucokinase-knockout mice, suggesting that glucagon release during hypoglycemia is controlled by glucokinase-mediated glucose sensing
outside the brain but not in b-cells. For epinephrine, we found increased responses in GCK-MODY patients, in b-cell ablated diabetic I366F mice
and in conditional (nestin lineage) brain glucokinase-knockout mice, supporting a role for brain glucokinase in triggering epinephrine release.
Conclusions: Our data suggest that glucokinase in brain and other non b-cell peripheral hypoglycemia sensors is important in glucose ho-
meostasis, allowing the body to detect and respond to a falling blood glucose.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Original Article1. INTRODUCTION
Maintaining blood glucose within an appropriate range is crucial for
survival. In diabetes, those who suffer episodes of severe hypogly-
cemia have an increased risk of death [1,2]. The brain is especially
dependent on an adequate, continuous supply of circulating glucose to
fuel metabolism and support function. To defend against falling blood
glucose, a series of robust counter-regulatory responses normally
prevent hypoglycemia from occurring [3]. These include the ability to
switch off endogenous insulin secretion as blood glucose levels start to
fall and release the key counter-regulatory hormones glucagon and
epinephrine. In order to detect and respond to changes in blood
glucose, a network of specialized glucose sensors in the periphery and
brain forms an integrated network to trigger counter-regulation as
hypoglycemia starts to develop [4].
The glucose-sensing apparatus in pancreatic b-cells includes the low
affinity hexokinase glucokinase (GCK), which controls glycolytic flux
into downstream metabolic sensing by ATP-gated potassium (KATP)
channels. In the canonical b-cell pathway, a fall in glucose is detected
as a fall in this metabolic flow, with opening of KATP channels leading to
an early cessation of insulin release from b-cells [5].
If blood glucose falls further, glucagon release during hypoglycemia
probably has a redundancy of controlling inputs. a-cells contain GCK
and KATP channels and may sense hypoglycemia directly [6,7]. a-cells
also likely receive information from local paracrine signalling and/or
direct contact from b and d-cells within islets [7e10]. Additionally,
circulating catecholamines and pancreatic neural autonomic innerva-
tion may contribute to a coordinated homeostatic glucagon response
[11,12].
Epinephrine release as part of a sympatho-adrenal response to hy-
poglycemia is driven by increased outflow from the brain to the adrenal
medulla [4]. Brain glucose sensors may be glucose-excited (GE) or
inhibited (GI) [13]. Counter-regulatory responses may be triggered
either by hypoglycemia-induced GI activation and/or GE silencing.
Glucose sensing in brain sensors may employ mechanisms similar to
those identified in the beta cell including GCK [14e20].
Here we examined the role of GCK in the hormonal counter-regulatory
protection against hypoglycemia, examining responses in mice and
humans with defined molecular disruptions (mutations or ablation) of
GCK. We hypothesized that reducing GCK activity would reduceTable 1 e Group characteristics and baseline hormone levels for participants u
GCK-MODY Type 2 diabetes p-value GCK-MO
vs Type 2 diabet
Number 8 6 e
Female/Male 6/2 4/2 e
Age 41.5  4.1 46  4.0 0.2
BMI/kg m2 31.8  2.4 31.7  3.0 0.6
FPG/mmol L1 7.0  0.6 7.2  1.1 0.9
HbA1c/% mmol mol1 6.4  0.5
46  5.5
7.4  1.0
57  11
0.06
Treatment Diet 7,
Sulphonylurea 1
Diet 2,
Sulphonylurea
2, Metformin 2
C-peptide/mmol L1 862  356 1120  566 0.8
Epinephrine/nmolL1 0.29  0.1 0.38  0.2 0.2
Norepinephrine/nmolL1 2.1  0.2 2.0  0.5 0.4
Pancreatic
polypeptide/pmolL1
15.1  8.1 34.1  43.0 0.4
Glucagon/pg ml1 96  15 131  45 0.07
Cortisol/nmol L1 295  133 343  209 0.8
Growth Hormone/mu L1 5.1  4.9 1.5  0.9 0.3
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trigger earlier and/or increased counter-regulation compared with
controls during controlled matched hypoglycemic challenges. We
studied humans and mice, using defined molecular perturbations in
the latter to gain further insight into the sites where GCK-mediated
glucose sensing plays a role in counter-regulatory responses.
2. MATERIAL AND METHODS
2.1. Human Participants
We studied eight participants with GCK-MODY (Maturity Onset Dia-
betes of Young due to heterozygous inactivating mutations of the GCK
gene), comparing responses with data collected from eight healthy
controls and six participants with type 2 diabetes matched for fasting
plasma glucose with GCK-MODY participants. All three groups were
matched for age (5 years), gender, and BMI (10%). Data from the
group with type 2 diabetes and seven of the healthy control group have
been previously published [21]. The subjects in the present report were
all studied in random order during the same time period. The char-
acteristics of these participants and basal hormone concentrations are
shown in Table 1. Details of identified mutations in GCK-MODY group
are listed in Supplementary Table 1. The study was performed in
accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) and was approved in advance by a local in-
dependent ethics committee. All participants gave informed written
consent prior to the start of the study.
2.2. Murine models
We studied three mouse models with targeted disruption of GCK. All
mice were maintained on a 12 h dark cycle with ad libitum access to
food and water except where indicated. All animal studies complied
with ARRIVE guidelines and were performed in accordance with the
U.K. Animals (Scientific Procedures) Act, 1986 (Amended 2012) and
associated guidelines, EU Directive 2010/63/EU for animal experi-
ments following ethical review by the University of Cambridge Animal
Welfare and Ethical Review Body (AWERB).
2.2.1. Gck-mutant mice
Mice with an isoleucine to phenylalanine mutation (I366F) created by
ethyl-nitrosourea mutagenesis were backcrossed onto a BALBc/C3Hndergoing hypoglycemic clamps.
DY
es
Healthy controls p-value GCK-MODY
vs Healthy controls
p-value Type 2
Diabetes vs Healthy controls
8 e
6/2 e
41.5  4.9 0.8
28.8  1.8 0.5
4.5  0.8 0.0008 0.002
5.6  0.5
38  5.5
0.01
None
694  233 0.2 0.1
0.21  0.1 0.07 0.07
2.0  0.8 0.9 0.8
20.0  16.3 0.5 0.6
98  38 0.8 0.1
255  83 0.6 0.7
2.2  2.9 0.2 1.0
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
background (Charles River, UK). Homozygote (HOM), heterozygote
(HET) and wild type (WT) littermates were studied [22].
2.2.2. b-cell ablated Gck-mutant mice
To determine whether observations from Gck mutant mice (and GCK-
MODY humans) were related to altered GCK activity in pancreatic b-
cells or other sites such as brain, we examined responses to hypo-
glycemia in I366F mice with b-cells ablated by streptozotocin (STZ).
Starting at age 3 weeks, female I366F mice received a single ip dose of
200 mg/kg of STZ and were monitored for the development of hy-
perglycemia. We aimed to create a model of insulin-dependent dia-
betes while avoiding uncontrolled hyperglycemia in animals and
matching glycemic exposure prior to studying. To achieve this, where
diabetes developed, mice were treated with once daily insulin levemir
(Detemir, NovoNordisk, Crawley, UK) with insulin doses adjusted in
individual animals according to tail-vein sampling aiming for glucose
values of approximately 15 mM. After 5 weeks of therapy, animals
underwent surgery and clamp studies as described below.
2.2.3. Conditional brain Gck knock out mice
Conditional brain Gck knock out (brain GCKKO) mice were created by
crossing mice expressing Cre recombinase under the nestin promoter
and CNS-specific enhancer (NesCre) with Gck-floxed (GKlox) mice (North
Carolina MMRRC repository) on C57BL/6 background [23,24].
2.3. Hypoglycemic Clamp Studies in Human Participants
Participants were admitted to the investigation unit at The Royal Devon
and Exeter Hospital on the morning of the study after a 10 h overnight
fast, having omitted any regular medication for at least 12 h prior to the
test. A retrograde catheter was placed in a peripheral vein of the non-
dominant hand and maintained in a heated sheepskin hand warmer to
arterialize venous blood. A second catheter, for later infusion of insulin
and glucose, was placed in the antecubital fossa of the same arm. At
least 30 min after placing the catheters, five arterialized blood samples
were drawn at 10-minute intervals for baseline measurement of
glucose and counter-regulatory hormones.
Studies were performed as previously described [25]. In brief, a
primed-continuous infusion of regular human insulin in 0.9% saline
containing 4% autologous blood was infused at a rate of 1.5 mU
kg1min1 for the duration of the study. Whole blood glucose was
measured at the bedside every 5 min and controlled by adjustment of a
simultaneous intravenous infusion of 20% glucose.
Blood glucose was reduced to 5 mmolL1 from the fasting level and
stabilized over the first 40 min of the clamp. It was then reduced
stepwise to 4.4, 3.8, 3.4, 2.8, and 2.4 mmolL1 before being restored
to 5 mmolL1. Each step lasted for 40 min except the nadir, which
lasted for 20 min. Arterialized blood was collected for counter-
regulatory hormone analysis at the midpoint, third quartile and end
of each step. Symptoms were assessed using a linear analogue scale
on a standard questionnaire at the midpoint and end of each glucose
step.
2.4. Hypoglycemic clamp studies in I366F mice
For clamps, six-week old male I366F mice underwent hyper-
insulinemic hypoglycemic clamp studies as previously described (but
here without donor blood infusion) [26]. In summary, 1 week after
surgical placement of arterial and venous catheters, mice were studied
conscious and free-moving after a 6 h fast including acclimatisation to
study cages. Blood sampling was performed remotely without handling
mice through long lines attached to indwelling arterial catheters. Mice
received a 100 mU/kg bolus of Humulin S (Eli Lilly, Basingstoke, UK)MOLECULAR METABOLISM 17 (2018) 17e27  2018 The Authors. Published by Elsevier GmbH. This is an
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expected differing baseline glucose values between genotypes, plasma
glucose was adjusted in all 3 groups to 5 mM during the initial 45 min
and then lowered over the following 45 min to a nadir of 3 mM. At the
end of studies, a sample was drawn for assay of plasma insulin (also
measured at baseline), glucagon and epinephrine. To examine the
potential effects of study conditions on counter-regulatory hormones, a
further control group of HET mice underwent surgical catheterisation
but had “dummy clamps” with blood sampling but no infusions on
study days (designated SAMP).
2.5. Hypoglycemic clamp studies in b-cell ablated I366F mice
After 5 weeks of insulin therapy, animals underwent surgery and
clamp studies as above except using single jugular venous catheters to
reduce surgical time and optimise post-operative recovery in poten-
tially fragile insulin-dependent diabetic animals. Hypoglycemic clamps
were therefore performed for this study on conscious animals using a
semi-restraint technique with tail vein sampling as previously
described [26]. At the end of studies, pancreata were removed for
assay of insulin content and compared with non-STZ controls sacri-
ficed ad libitum.
2.6. Hypoglycemic clamp studies in brain GCK knock out mice
Three groups of male mice (brain GCKKO, NesCre and GCKlox controls)
were studied aged 6e8 weeks. As above, overnight-fasted semi-
restrained venous-catheterised mice underwent hyperinsulinemic hy-
poglycemic clamp studies. In these studies, we used a lower insulin
dose of 10mU/kg/min, anticipating greater whole body insulin sensi-
tivity compared with I366F mice which have altered hepatic GCK [23].
Plasma glucose was gradually reduced to approximately 3 mM and
maintained at this level for 60 min. At the end of the studies, samples
were collected for assay of plasma insulin, glucagon, and epinephrine.
2.7. Blood assays
In rodent studies, plasma glucose was measured using an Analox GM-
9 analyser (Analox Instruments, London UK). Insulin and glucagon were
measured by RIA (Linco) and epinephrine by ELISA (IBL Hamburg,
Germany), or HPLC as previously described [27]. In human clamps, we
measured whole blood glucose at bedside using a Yellow Springs
glucose analyzer (Yellow Springs Instruments, Yellow Springs, Ohio);
catecholamines by high performance liquid chromatography with
electrochemical detection [28]; cortisol by radioimmunoassay [29];
glucagon (Diagnostic Products, Los Angeles USA), C-peptide (Linco, St
Louis Mo USA) and pancreatic polypeptide using commercial radio-
immunoassay kits, and growth hormone using a commercial immu-
noradiometric assay (Netria, London).
2.8. Glucose phosphorylation assay
Animals were sacrificed at the beginning of light cycle. Tissue was
homogenized in lysis buffer (50 mM HEPES, 150 mM KCl, 1 mM
dithiothreitol (DTT), 4 protease inhibitor cocktail tablets (Roche), pH
7.4) on ice. Homogenates were centrifuged twice (14,000 rpm for
15 min at 4 C) and supernatant stored at 80 C until required.
Protein concentration was estimated against BSA standards using
Bradford protocol [30].
Glucose phosphorylation was determined by coupling the glucose
phosphorylation activity of GCK to the oxidation of glucose 6-phosphate
by glucose 6-phosphate dehydrogenase with concomitant reduction of
NADþ to NADH detected at 340 nm. The reaction was started by
adding 400 mg (peripheral tissues) or 20 mg (brain) extract to reaction
cocktail (100 mM HEPES (pH 7.4), 5 mM ATP, 6 mM MgCl2, 0.05%open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 19
Original ArticleBSA, 150 mM KCl, 1 mM DTT, 1 mM NADþ, 5 U/ml G6PD) supple-
mented with 0.5 mM and 6 mM (peripheral) or 2.5 mM (brain) glucose,
to a final volume of 100 ml. Absorbance was measured at 340 nm over
60 min on a Fusion Universal Microplate Analyser at 37 C. Glucose
phosphorylating activity of GCK was then calculated by deducting the
amount of glucose phosphorylation at 0.5 mM glucose (attributed to
low Km hexokinase activity).
2.9. GCK mRNA expression in mice
Tissues were homogenised in RNA Stat-60 (Amsbio, UK) and RNA was
extracted using chloroform, precipitated with isopropanol and re-
suspended in RNase-free water. cDNA was synthesized from 500 ng
RNA using the final reaction mix of 50 ng random hexamer primers,
1.25 mM dNTPs, 200U M-MLV reverse transcriptase (Promega, UK),
1 RT buffer (Promega) and 2.5 mM MgCl2 in a final volume of 20 ml.
Primer sequences are detailed in Supplementary Table 1. All samples
were analysed in duplicate and average cycling threshold (Ct) units
were obtained as the average of the results. 18s was used as an in-
ternal control, and the other housekeeping genes were analyzed using
the Bestkeeper algorithm, which was used to normalize data of the GK
gene.
2.10. Data analysis
For human studies, we calculated peak hormone levels as the highest
value achieved for each hormone. Because of the high degree of in-
dividual variability, we corrected these levels for baseline and
expressed them as incremental rise over baseline for each individual.
We calculated area under the curve (AUC) for each hormone between
40 and 220 min (the time of matched hypoglycemia during the clamp)
as an increment above the hormone value at 40 min. We determined
glucose thresholds for hormone responses as the glucose level at
which there was a sustained increase of 3 standard deviations over
the mean of five baseline measurements for a specific hormone as
previously described [21]. We defined thresholds for the development
of autonomic, neuroglycopenic and total (sum of autonomic and
neuroglycopenic) symptoms as the plasma glucose levels at which
symptom scores increased by  2 points over baseline on two
consecutive assessments [31]. When no threshold was defined for an
individual, we used the glucose nadir achieved during the clamp for
that subject’s contribution to group statistical analyses. To allow for the
confounding effect of prevalent hyperglycemia on hypoglycemic re-
sponses, the main comparison was with the glycemia-matched pa-
tients with type 2 diabetes. We compared results between groups
using the ManneWhitney U test.
As described above, each of our three murine models (I366F, b-cell
ablated I366F and brain GCKKO) were studied on different genetic
backgrounds or gender, which may impact on brain transcriptome and
physiological responses to hypoglycaemia [32,33]. Statistical analyses
were therefore performed within each of these three studies
(comparing littermate controls studied in parallel and contemporane-
ously) with no statistical comparison between murine studies. Rodent
data were analyzed and plotted using GraphPad Prism version 4
(GraphPad Software Inc, San Diego, California, USA). For statistical
analysis, data were analyzed by either; (i) one-way ANOVA using post-
hoc Tukey’s to compare all pairs of columns, (ii) one-way ANOVA using
post-hoc Dunnett’s to compare all columns to control, (iii) two-way
ANOVA with post-hoc Bonferroni test or (iv) student’s t-test as
appropriate. Significance level was P < 0.05 throughout. Data are
expressed as means  SEM unless otherwise stated.20 MOLECULAR METABOLISM 17 (2018) 17e27  2018 The Authors. Published by Elsevier G3. RESULTS
3.1. GCK-MODY humans have increased counter-regulatory
responses to hypoglycemia
Mean blood glucose profiles of the three groups obtained during the
clamp are shown in Figure 1A. Importantly, there was no significant
difference in fasting glucose between GCK-MODY
(6.6  0.6 mmol L1) and T2D groups (6.7  0.9 mmol L1,
p ¼ 0.8) nor at any step during the clamp. As expected, baseline
fasting blood glucose values were lower in healthy controls
(4.6  0.6 mmolL1, p ¼ 0.002 vs GCK-MODY; p ¼ 0.003 vs T2D).
From 40 min onwards in clamp studies, there were no significant
differences in blood glucose values between the three groups. Exog-
enous glucose infusion requirements during clamp studies were
similar in the GCK-MODY (394  249 mmol) and T2D
(232  212 mmol; p ¼ 0.2) groups with both groups requiring
significantly less glucose during the course of the clamp compared to
healthy controls (903  449 mmol, p ¼ 0.03 vs GCK-MODY;
p ¼ 0.007 vs T2D).
The GCK-MODY group had an earlier onset (higher glucose at threshold
of glucagon release; p ¼ 0.007) and greater peak glucagon response
(p ¼ 0.03) than the T2D group (Table 2a and Figure 1C). Compared
with healthy controls, the GCK-MODY group also had an earlier onset
(p ¼ 0.002), greater peak incremental glucagon response (p ¼ 0.046)
and greater AUC (p ¼ 0.01). The GCK-MODY group also had a greater
peak epinephrine rise (p ¼ 0.03) and AUC for epinephrine (p ¼ 0.005)
compared with the T2D group (Tables 2a and b and Figure 1D).
Compared with the healthy controls, the GCK-MODY group had earlier
onset (p ¼ 0.009) and greater incremental peak (p ¼ 0.03) and AUC
(p ¼ 0.001) for epinephrine responses (Table 2a and b & Figure 1D).
There was no difference in glucose threshold (p ¼ 0.07), AUC or peak
epinephrine response between the between the T2D groups and
healthy controls (Tables 2a and b and Figure 1D).
There was no difference between the GCK-MODY and T2D groups for
other measured counter-regulatory hormones (Tables 2b and c). C-
peptide suppression was greater in patients with GCK-MODY
compared to T2D and healthy controls at each time point from
120 min (Figure 1B) (GCK vs T2D, p¼ 0.04; GCK vs healthy, p¼ 0.02)
to 260 min (GCK vs T2D, p¼ 0.007; GCK vs healthy, p¼ 0.006). There
were no differences in the glucose threshold of total, autonomic or
neuroglycopenic symptoms of hypoglycemia between the GCK-MODY
and T2D groups (Table 2c and Figure 1E). The GCK-MODY had earlier
onset of total (p ¼ 0.002) autonomic (p ¼ 0.002) and neuroglycopenic
(p ¼ 0.02) symptoms compared with healthy controls (Table 2c).
In summary, data from GCK MODY humans were consistent with our
hypothesis that GCK-mediated sensing of hypoglycemia contributes to
the integrated glucagon and epinephrine counter-regulatory response
to a falling blood glucose. Given the whole body GCK mutations seen in
GCK MODY patients, we then aimed to examine further the contribu-
tions from different glucose sensing sites by using murine models.
3.2. I366F GCK mutant mice show amplified glucagon response to
hypoglycemia
We first examined I366F mice with a point mutation in GCK. As ex-
pected in this whole body GCK-mutant mouse model, we found
reduced glucose phosphorylating activity in liver and pancreas of both
heterozygous (HET) and homozygous (HOM) I366F mice compared to
wild type (WT) littermates (Supplementary Figures 1a and b). Glucose
phosphorylating activity measured ex vivo at a physiological brain-mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1: Hypoglycemic Clamp Studies in Human Participants: A) Whole blood glucose; B) c-peptide; C) glucagon; D) epinephrine and E) symptoms scores during the
hyperinsulinemic, hypoglycemic clamp studies. Key: (GCK MODY) black squares, type 2 diabetes (type 2) grey triangles and non-diabetic controls [18] open squares, shown as
mean  SE.glucose level (2.5 mM) was lower in hypothalamus of both HET and
HOM I366F mice compared to WT (Figure 2A). Quantitative PCR also
showed reduced GCK mRNA levels in hypothalamus and liver of both
HET and HOM mice compared to WT (Supplementary Figures. 1c and
d). Analogous with human GCK-MODY, ad libitum blood glucose wasTable 2a e Peak incremental counter-regulatory hormone rise above baseline
GCK-MODY Type 2 diabetes p-value GC
vs Type 2
Glucagon/pg ml1 127  88 42  30 0.03
Epinephrine/nmol L1 5.5  2.5 2.8  1.4 0.03
Norepinephrine/nmol L1 2.4  1.9 1.7  1.1 0.5
Cortisol/nmol L1 540  249 458  197 0.6
Growth Hormone/mu L1 42  50 22  13 0.4
Pancreatic polypeptide/pmol L1 192  120 343  275 0.4
Table 2b e Incremental Area Under the curve (AUC) for counter-regulatory hor
GCK-MODY Type 2 diabetes p-value
vs Type
Glucagon/pg ml1 10,070  8929 984  5412 0.01
Epinephrine/nmol L1 354  176 136  51 0.005
Norepinephrine/nmol L1 117  166 62  35 0.8
Cortisol/nmol L1 36,269  34,048 25,858  35,477 0.6
Growth Hormone/mu L1 2550  2159 1291  799 0.2
Pancreatic polypeptide/pmol L1 9632  5992 12,000  8880 0.7
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www.molecularmetabolism.comelevated in mice with mutant GCK (both HET and HOM in mice) with no
compensatory changes in insulin or glucagon (Supplementary
Figures 1eeg).
During clamp studies (Figure 2B), plasma glucose values were well
matched in all genotypes from 45 min onwards (Figure 2C). HOM andSD.
K-MODY
diabetes
Healthy controls p-value GCK-MODY
vs Healthy controls
p-value
Type 2 diabetes vs
Healthy controls
43  40 0.046 1.0
2.9  1.9 0.03 0.8
1.6  0.7 0.5 0.7
312  142 0.046 0.12
44  21 0.1 0.03
165  208 0.5 0.6
mone release (from 40 to 220 min)  SD.
GCK-MODY
2 diabetes
Healthy controls p-value GCK-MODY
vs Healthy controls
p-value
Type 2 diabetes vs
Healthy controls
416  4148 0.01 0.8
69  65 0.001 0.09
26  40 0.07 0.09
1973  17,044 0.02 0.09
445  1345 0.04 0.2
1261  1294 0.001 0.003
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Figure 2: Hypoglycemic clamp studies in I366F mice. (A) Effect of GK gene mutation on hypothalamic glucose phosphorylating activity of I366F mice. (B) Schematic of study
design from surgery on day 1 through to hypoglycemic clamp on day 6. (C) Plasma glucose and (D) dextrose infusion rates during hypoglycemic clamp studies. (E) Plasma glucagon
and (F) epinephrine responses at the end of hypoglycemic clamp studies. White circles ¼ WT; black diamonds/dashed line ¼ HET; black squares ¼ HOM. ‘SAMP’ represents
dummy clamp mice with sampling only. All data are fromw8-week-old male mice presented as mean  SEM, n ¼ 6e10 in each group, *p < 0.05, **p < 0.01, ***p < 0.001.
See also Supplementary Figure 1.
Table 2c e Glucose thresholds for counter-regulatory hormone release and total symptoms  SD.
GCK-MODY
(mmol L1)
Type 2 diabetes
(mmol L1)
p-value
GCK-MODY vs
Type 2 diabetes
Healthy controls
(mmol L1)
p-value
GCK-MODY vs
Healthy controls
p-value
Type 2 diabetes vs
Healthy controls
Glucagon 3.6  0.5 2.9  0.3 0.007 2.6  0.3 0.002 0.12
Epinephrine 4.0  0.6 3.7  0.5 0.4 3.2  0.9 0.009 0.07
Norepinephrine 3.2  0.5 3.5  0.5 0.4 2.7  0.4 0.03 0.01
Cortisol 3.7  0.9 3.6  1.2 0.6 2.7  0.5 0.02 0.09
Growth Hormone 3.6  0.5 3.6  0.3 0.6 2.6  1.2 0.02 0.01
Pancreatic polypeptide 3.5  0.5 3.5  0.3 1.0 2.8  0.5 0.01 0.005
Total symptoms 3.6  0.7 3.5  0.9 0.8 2.6  0.3 0.002 0.02
Autonomic symptoms 3.5  0.4 3.4  0.9 0.4 2.6  0.3 0.002 0.02
Neuroglycopenic symptoms 3.0  0.4 2.9  0.4 0.4 2.6  0.3 0.02 0.16
Original ArticleHET mice required significantly less dextrose than WT mice, likely due to
hepatic insulin resistance/reduced hepatic glucose uptake secondary to
mutant GCK (Figure 2D). Consistent with our hypothesis, I366F HOM
mice showed increased glucagon responses to acute hypoglycemia
(Figure 2E). This increase was specific for hypoglycemia, as levels were
not raised in non-hypoglycemic mice (SAMP). In these studies, there
was no effect of genotype on epinephrine responses (Figure 2F).
3.3. Amplified hypoglycemia counter-regulation in I366F GCK
mutant mice is not due to abnormal b-cell GCK
GCK-MODY humans and I366F mice have a whole body GCK mutation
and it is possible that abnormal b-cell GCK and reduced intra-islet
paracrine (insulin) signalling contribute to increased glucagon re-
sponses. To address this, we examined responses to hypoglycemia in
I366F mice that had undergone b-cell ablation with high dose STZ.
Importantly, we subsequently treated animals with insulin to match
carefully glycemia in all genotypes. As anticipated, STZ therapy
resulted in almost undetectable pancreatic insulin content
(Supplementary Figure 2). By careful titration of daily insulin dosing, we22 MOLECULAR METABOLISM 17 (2018) 17e27  2018 The Authors. Published by Elsevier Gwere able to match blood glucose levels after STZ therapy for 4 weeks
prior to clamp studies in all genotypes (Figure 3A,B). Insulin doses
were individualized and HOM mice needed more insulin than other
genotypes to achieve similar glycemia (Figures 3C), likely explained at
least in part by altered hepatic substrate flux as described previously in
hepatic Gck KO mice [23].
During clamp studies in STZ-treated I366F mice, starting plasma
glucose values similar in all groups and well matched during studies
(Figure 2D). Plasma insulin values at baseline were similar (2.6  0.9,
2.5  0.8, 2.0  0.2 ug/l; WT, HET, HOM) and rose during clamp
studies with no differences between groups (peak values 17  4,
27 10, 22 3 ug/l; WT, HET, HOM respectively). HET and HOM mice
required less dextrose during clamp studies to achieve similar glucose
profiles (Figure 3E). As anticipated, HET and HOM mice demonstrated
significantly greater glucagon and epinephrine responses to hypogly-
cemia compared with WT (Figure 3F,G). In summary, these data show
that the increased glucagon counter-regulatory response to hypogly-
cemia in mutant I366F mice is not simply due to altered GCK activity
(and insulin release/glycemia) in pancreatic b-cells.mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 3: Hypoglycemic clamp studies in beta-cell ablated I366F Mice. (A) Schematic diagram of study design with 200 mg/kg of streptozotocin given I.P. at weaning. (B) Based
on blood glucose sampling from the tail vein, (C) O.D. insulin detemir (levemir) doses were titrated. (D) Plasma glucose profile and (E) dextrose infusion rates during hypoglycemic
clamp studies. (F) Plasma glucagon and (G) epinephrine responses to clamped hypoglycemia. White circles ¼ WT, black diamonds/dashed line ¼ HET, black squares¼ HOM. Clamp
data are from w8-week-old male mice, presented as mean  SEM, n ¼ 9e11 in each group, *p < 0.05, **p < 0.01, ***p < 0.001. See also Supplementary Figure 2.3.4. Conditional brain GCKKO mice have an amplified counter-
regulatory response to hypoglycemia
To examine further the distinct role for brain GCK in hypoglycemia
counter-regulation, we studied a conditional brain GCKKO mouse
model. First, we confirmed the absence of brain Gck mRNA in brain
GCKKO mice (Figure 4A,B). During hypoglycemic clamp studies in
brain GCKKO mice, there were no differences between GCKlox and
NesCre control groups for any parameters examined; thus, clamp data
are shown as brain GCKKO versus combined controls (pooled GCKlox
and NesCre). Plasma glucose levels were well matched in brain GCKKO
and control groups throughout the clamp studies (Figure 4D).
Baseline counter-regulatory hormone levels were similar (glucagon
30  3 vs 25  2 pg/ml; epinephrine 1153  269 vs
1370  303 pg/ml; controls vs brain GCKKO). Plasma insulin levels at
baseline were also comparable (0.1 0.1 vs 0.1 0 ug/l; controls vs
GCKKO) and rose during clamp studies to a peak value with no dif-
ference between groups (2.0  0.3 vs 1.4  1.4 ug/l; controls vs
brain GCKKO). Brain GCKKO mice required significantly less dextrose to
maintain hypoglycemia during the late phase of clamp studies
(Figure 4E), suggesting amplified counter-regulatory responses to
hypoglycemia. In keeping with this, brain GCKKO mice showed a
higher epinephrine response to acute hypoglycemia compared to
controls (Figure 4G). No differences in glucagon response were
observed (Figure 4F).MOLECULAR METABOLISM 17 (2018) 17e27  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.com4. DISCUSSION
Our data reveal that a GCK-dependent glucose-sensing mechanism
operates during hypoglycemia in both humans and mice. This mech-
anism facilitates three key protective responses to a falling glucose,
being involved in (i) the hypoglycemia-associated reduction in insulin
secretion and release of the counter-regulatory hormones (ii) glucagon
and (iii) epinephrine.
The ability to switch off endogenous insulin release during falling blood
glucose is an important and sometimes under-appreciated defence
against hypoglycemia. Consistent with an important role for GCK in beta
cell glucose-sensing, humans with GCK-MODY showed greater sup-
pression of C-peptide beginning at low normal blood glucose concen-
trations (from 3.8 mmolL1) compared with T2D and healthy controls.
While not unexpected that insulin secretion is influenced by the pres-
ence of a GCK mutation, to our knowledge, this is the first time that a
different effect on endogenous insulin secretion between GCK-MODY
and T2D has been demonstrated in vivo during acute hypoglycemia.
Supporting a role for GCK in mediating glucagon release, we observed
increased glucagon responses in GCK-MODY and I366F mice with
whole body reduced GCK activity. A previous study of GCK-MODY also
reported increased glucagon (but not epinephrine) responses during
experimental hypoglycemia, although hypoglycemic challenges were
not matched between groups [34]. Glucagon release from a-cellsopen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 23
Figure 4: Hypoglycemic clamp studies in conditional Brain GCKKO mice. (AeB) GCK mRNA expression level in hypothalamus and cortex of Brain GCKKO mice and control
littermates. (C) Schematic diagram of hypoglycemic clamp design in conditional Brain GCKKO mice. (D) Plasma glucose profile and (E) Dextrose infusion rates during hypoglycemic
clamp studies. (F) Plasma glucagon and (G) epinephrine responses to clamped hypoglycemia. Black squares, Brain GCKKO; open circle, controls. Control represents pooled group of
GCKlox and NesCre mice. Data presented as mean  SEM in 6e8-week old mice, n ¼ 5 in each group for qRT-PCR data and 13 to 14 in each group for clamp studies, *p < 0.05,
**p < 0.01, ***p < 0.001.
Original Articleduring hypoglycemia may be triggered both by direct a-cell sensing of
glucose, local paracrine signalling from within islets and distal factors
such as autonomic pancreatic innervation and circulating factors such
as catecholamines [8]. This means that intra-islet GCK found in a- and
b-cells and GCK at distal sensing sites such as brain could all
potentially contribute to counter-regulatory glucagon responses. Here,
we found that increased glucagon responses to hypoglycemia per-
sisted in I366F mice following b-cell ablation, suggesting that local
paracrine signalling from pancreatic b-cells was not necessary to
mediate effects of mutant GCK. We saw no differences in glucagon
responses in our brain GCKKO model suggesting that brain GCK was not
predominantly involved in glucagon responses to hypoglycemia. Taken
together, these data are consistent with direct GCK-mediated sensing
of hypoglycemia by a-cells being an important part of the counter-
regulatory glucagon response. In keeping with this, a recent paper
described mice with a-cell GCK knockout displaying increased
glucagon levels, although responses to hypoglycemia were not re-
ported [35]. Our findings do not preclude other non-GCK brain glucose
sensing, for example using GLUT-2, contributing to the central
glucagon response [36,37].
Epinephrine responses to hypoglycemia are probably triggered cen-
trally, perhaps with input from peripheral hypoglycemia sensing [3,4].24 MOLECULAR METABOLISM 17 (2018) 17e27  2018 The Authors. Published by Elsevier GWe observed increased epinephrine responses in GCK-MODY and
I366F diabetic mice. Consistent with a role for brain GCK in detecting a
low blood glucose, we also saw increased epinephrine responses to
hypoglycemia in brain GCKKO mice. It is unclear why there were no
observed differences in epinephrine responses to hypoglycemia in
I366F mice given the findings in the other 3 models studied. The clamp
protocol in I366F mice was different from that used for I366F diabetic
and brain GCKKO mice. However, we would anticipate that the double
catheter technique with mice being free moving and unhandled would
carry less potential for the confounding effects of stress from study
conditions. In these murine studies, we were limited by sampling
volumes to a single measure of counter-regulation at the end of studies
and it is possible that a more complete time series might have
unmasked differences.
Brain GCK expression is restricted to key brain glucose-sensing areas
including areas in the basomedial hypothalamus such as the ARC and
VMN [16e19]. A recent study examined electromagnetic inhibition of
VMN GCK-neurons, finding blunted hyperglycemic response to 2-
deoxyglucose induced glucopenia (although individual counter-
regulatory hormone responses were not reported) [38]. A previous
study used short hairpin RNA-knockdown of VMN GCK in rats,
reporting increased epinephrine responses to non-clamped (insulin-mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
bolus induced) hypoglycemia [39]. It is possible that VMN neurons
involved in GCK-mediated counter-regulation will be non-SF1 cells
given that genetic inactivation of GCK specifically within VMN SF1 cells
does not increase epinephrine or glucagon release in response to
hypoglycemia [40].
We did not see significantly different responses between GCK-MODY
and T2D groups for the other measured counter-regulatory hor-
mones in human studies. This suggests either that GCK is less
important in these responses and/or that adaptation occurs. Tran-
scriptional profiling of hypothalamic GCK cells in a model revealed a
population of hypoglycemia-activated growth hormone releasing hor-
mone cells, suggesting a role for brain GCK in generating growth
hormone responses to hypoglycemia [20]. It is unclear if this reflects
species differences. Given the volumes required for sampling, it was
not possible to measure additional hormones in our mice models.
Two studies in humans examined brain GCK and hypoglycemia indi-
rectly, using fructose infusion and hypothesizing that this acted via
increased brain fructose-6 phosphate to activate GCK regulatory pro-
tein (GKRP), leading in turn to inhibition of brain GCK. Systemic fructose
infusion amplified glucagon and epinephrine responses to hypogly-
cemia in healthy subjects and increased epinephrine responses in
patients with type 1 diabetes [41,42]. However, it is unclear whether
brain GCK inhibition is indeed the mechanism of action of fructose
which may have other actions such as hypothalamic AMPK activation
[43]. The strengths of our experimental approach are that we studied
defined molecular perturbations in GCK and used insulin clamp
techniques across all models to create carefully controlled and
matched hypoglycemic challenges (as opposed to insulin bolus-
induced hypoglycemia or glucoprivation).
Of note, each of our three murine models (I366F, b-cell ablated I366F
and brain GCKKO) were studied on different genetic backgrounds and/
or gender. Previous data have shown quantitative differences between
strains in the magnitude and threshold of counter-regulatory re-
sponses to hypoglycemia [32]. We used female mice in our strepto-
zotocin studies to maximize efficient use of the I366F breeding colony.
Gender differences in counter-regulation have been reported in human
and murine studies [40,44]. It is thus possible that background strain
and/or gender might have altered our findings.
A number of GCK activators for treating T2D have been developed and
tested but not progressed successfully from clinical trials into therapy
[45]. Our observations suggest that increased risk of hypoglycemia
might be possible, particularly if drugs penetrate into brain. A further
possibility is that GCK inhibition could offer a therapeutic approach to
increase hypoglycemia counter-regulatory defences in diabetes.
Our findings also provide a physiological explanation for observations
seen in clinical practice when treating GCK-MODY diabetes, where
there is a reduced response to exogenous insulin including during
pregnancy [46,47]. We found that insulin suppression and glucagon
release occur at a higher glucose levels in GCK-MODY than T2D and
that there is an exaggerated epinephrine response to glucose lowering
in GCK-MODY. This supports the clinical observations that large doses
of insulin may be needed to achieve pregnancy glucose targets in
women with GCK-MODY and those who reach pregnancy glucose
targets frequently report autonomic symptoms of hypoglycemia [per-
sonal communications ATH & MH Shepherd].
5. CONCLUSIONS
Our data identify a GCK-dependent glucose-sensing mechanism dur-
ing hypoglycemia that boosts responses to falling glucose; augmenting
hypoglycemia-associated reduction in insulin secretion and the releaseMOLECULAR METABOLISM 17 (2018) 17e27  2018 The Authors. Published by Elsevier GmbH. This is an
www.molecularmetabolism.comof the counter-regulatory hormones glucagon and epinephrine.
Moreover, we reveal a specific function of GCK in defined sub-regions
that regulate these three effects. Our data suggest that b-cell GCK is
responsible for insulin suppression as blood glucose levels fall,
whereas GCK outside the b-cell (likely in pancreatic a-cells) is
necessary for a normal glucagon response and GCK within brain
glucose-sensing areas contributes to epinephrine responses to hy-
poglycemia. These findings are relevant to the treatment of the
growing global diabetes epidemic.
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